| NCT ID | NCT06882850 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Unidade Local de Saúde de Coimbra, EPE |
| Condition | Aspirin |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-02-01 |
| Primary Completion | 2025-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2024-02-01 with a primary completion date of 2025-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn about the effects of low dose aspirin in immunity Pregnant women taking aspirin for other reasons (preeclampsia prevention) will be studied. The main question it aims to answer is: evaluate the effect of LDA on the modulation of innate immunity cells (NK cells, monocytes, γδ T cells) and/or acquired immunity (B and T lymphocytes, Treg cells, Th cells). Participants already taking intervention A as part of their regular medical care for RA will answer online survey questions about their joint pain for 5 years.
Eligibility Criteria
Inclusion Criteria: - Singleton pregnancy * Patients attending prenatal consultations at the Obstetrics Service A of CHUC, with the first consultation occurring before 14 weeks of gestation * Gestational age determined by first-trimester ultrasound * Study group: Women classified as high risk for PE according to clinical/historical criteria and the Fetal Medicine Foundation algorithm. LDA-naïve. Exclusion Criteria: Multiple pregnancy * Autoimmune diseases * Prior use of LDA or other immunomodulatory medication before potential recruitment * History of spontaneous miscarriages and/or medical termination of pregnancy * Fetal malformation
Contact & Investigator
Ana L Areia, PhD MD
PRINCIPAL INVESTIGATOR
University of Coimbra
Frequently Asked Questions
Who can join the NCT06882850 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Aspirin. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06882850 currently recruiting?
Yes, NCT06882850 is actively recruiting participants. Contact the research team at analuisareia@gmail.com for enrollment information.
Where is the NCT06882850 trial being conducted?
This trial is being conducted at Coimbra, Portugal.
Who is sponsoring the NCT06882850 clinical trial?
NCT06882850 is sponsored by Unidade Local de Saúde de Coimbra, EPE. The principal investigator is Ana L Areia, PhD MD at University of Coimbra. The trial plans to enroll 30 participants.